Recent News

• 11.05.2026 - Voyager Reports Third Quarter 2026 Financial and Operating Results
• 10.27.2026 - Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
• 10.21.2026 - Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
• 09.01.2026 - Voyager to Present at Upcoming Investor Conferences
• 08.06.2026 - Voyager Reports Second Quarter 2026 Financial and Operating Results
• 07.13.2026 - Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
• 06.29.2026 - Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
• 06.11.2026 - Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
• 06.01.2026 - Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
• 05.13.2026 - Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

Recent Filings

• 11.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.02.2026 - 144 Report of proposed sale of securities
• 11.02.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.02.2026 - EX-99.1 EX-99.1
• 11.02.2026 - 8-K Current report
• 10.30.2026 - 144 Report of proposed sale of securities
• 10.30.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors